当前位置: X-MOL 学术Gastrointest. Endosc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Comparison between fine-needle biopsy and fine-needle aspiration for EUS-guided sampling of subepithelial lesions: a meta-analysis.
Gastrointestinal Endoscopy ( IF 7.7 ) Pub Date : 2019-07-30 , DOI: 10.1016/j.gie.2019.07.018
Antonio Facciorusso 1 , Sumsum P Sunny 2 , Valentina Del Prete 1 , Matteo Antonino 1 , Nicola Muscatiello 1
Affiliation  

BACKGROUND AND AIMS There is limited evidence on the diagnostic performance of EUS-guided fine-needle biopsy (FNB) sampling in patients with subepithelial lesions. The aim of this meta-analysis was to compare EUS-guided FNB sampling performance with FNA in patients with GI subepithelial lesions. METHODS A computerized bibliographic search on the main databases was performed through May 2019. The primary endpoint was sample adequacy. Secondary outcomes were diagnostic accuracy, histologic core procurement rate, and mean number of needle passes. Summary estimates were expressed in terms of odds ratio (OR) and 95% confidence interval (CI). RESULTS Ten studies (including 6 randomized trials) with 669 patients were included. Pooled rates of adequate samples for FNB sampling were 94.9% (range, 92.3%-97.5%) and for FNA 80.6% (range, 71.4%-89.7%; OR, 2.54; 95% CI, 1.29-5.01; P = .007). When rapid on-site evaluation was available, no significant difference between the 2 techniques was observed. Optimal histologic core procurement rate was 89.7% (range, 84.5%-94.9%) with FNB sampling and 65% (range, 55.5%-74.6%) with FNA (OR, 3.27; 95% CI, 2.03-5.27; P < .0001). Diagnostic accuracy was significantly superior in patients undergoing FNB sampling (OR, 4.10; 95% CI, 2.48-6.79; P < .0001) with the need of a lower number of passes (mean difference, -.75; 95% CI, -1.20 to -.30; P = .001). Sensitivity analysis confirmed these findings in all subgroups tested. Very few adverse events were observed and did not impact on patient outcomes. CONCLUSIONS Our results speak clearly in favor of FNB sampling, which was found to outperform FNA in all diagnostic outcomes evaluated.

中文翻译:

EUS指导的上皮下病变的细针穿刺活检和细针抽吸比较:一项荟萃分析。

背景与目的超声内镜引导下的细针穿刺活检(FNB)采样对上皮下病变患者的诊断性能仅有有限的证据。这项荟萃分析的目的是比较EUS指导的GI上皮下病变患者的FNB采样性能与FNA。方法截止到2019年5月,对主要数据库进行了计算机书目搜索。主要终点是样本是否充分。次要结果是诊断准确度,组织学核心采购率和平均穿针次数。简要估算以比值比(OR)和95%置信区间(CI)表示。结果纳入10项研究(包括6项随机试验),共669例患者。用于FNB采样的足够样本的合并率为94.9%(范围为92.3%-97.5%)和用于FNA的80.6%(范围为71.4%-89.7%;或为2。54; 95%CI,1.29-5.01;P = .007)。当可以进行快速现场评估时,在这两种技术之间没有观察到显着差异。FNB采样的最佳组织学核心采购率为89.7%(范围84.5%-94.9%),FNA的最佳组织学核心采购率为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <。 0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。007)。当可以进行快速现场评估时,在这两种技术之间没有观察到显着差异。FNB采样的最佳组织学核心采购率为89.7%(范围84.5%-94.9%),FNA的最佳组织学核心采购率为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <。 0001)。在进行FNB采样的患者中,诊断准确性显着更高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。007)。当可以进行快速现场评估时,在这两种技术之间没有观察到显着差异。FNB采样的最佳组织学核心采购率为89.7%(范围84.5%-94.9%),FNA的最佳组织学核心采购率为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <。 0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。两种技术之间没有观察到显着差异。FNB采样的最佳组织学核心采购率为89.7%(范围84.5%-94.9%),FNA的最佳组织学核心采购率为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <。 0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。两种技术之间没有观察到显着差异。FNB采样的最佳组织学核心采购率为89.7%(范围84.5%-94.9%),FNA的最佳组织学核心采购率为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <。 0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。FNB采样为7%(范围84.5%-94.9%),FNA为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <.0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。FNB采样为7%(范围84.5%-94.9%),FNA为65%(范围55.5%-74.6%)(OR为3.27; 95%CI为2.03-5.27; P <.0001)。在接受FNB采样的患者中,诊断准确性显着提高(OR为4.10; 95%CI为2.48-6.79; P <.0001),并且需要通过的次数较少(平均差为-.75; CI为95%,- 1.20至-.30; P = 0.001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。48-6.79; P <.0001),并且需要通过的次数更少(平均差异为-.75; 95%CI为-1.20至-.30; P = .001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。48-6.79; P <.0001),并且需要通过的次数更少(平均差异为-.75; 95%CI为-1.20至-.30; P = .001)。敏感性分析证实了所有测试亚组的这些发现。观察到极少的不良事件,并且不会影响患者的预后。结论我们的结果清楚地表明了FNB采样的优势,在所有评估的诊断结果中,FNB采样均优于FNA。
更新日期:2019-12-19
down
wechat
bug